Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Egg Freezing Pilot Study

This study has been completed.
Information provided by:
University Reproductive Associates Identifier:
First received: February 9, 2009
Last updated: July 20, 2011
Last verified: July 2011

February 9, 2009
July 20, 2011
February 2009
June 2010   (final data collection date for primary outcome measure)
Incidence of Biochemical Pregnancy
Same as current
Complete list of historical versions of study NCT00839839 on Archive Site
  • Recovery of viable oocytes
  • incidence of fertilization
  • embryo development (how many fertilized eggs undergo development to a more advanced stage)
  • clinical pregnancy (fetal pole visible on transvaginal ultrasound) per cycle
Same as current
Not Provided
Not Provided
Egg Freezing Pilot Study
Oocyte Cryopreservation in Assisted Reproduction

University Reproductive Associates is conducting a pilot study to study the technique of egg freezing. Your participation in this study will provide us with important information to allow us to offer this technology for women wishing to freeze their eggs before cancer treatments. Your participation will include a standard IVF cycle with your eggs being frozen for a brief period of time and then transferred back to you as usual. You will receive a significant reduction in your IVF cycle cost.

Not Provided
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Infertility
  • Egg Freezing
Procedure: Oocyte Vitrification
All oocytes retrieved will be vitrified (rapidly frozen) after egg retrieval. The oocytes will then be warmed on the same day and fertilized per standard IVF-ICSI. Resulting embryos will be transferred back to the patient as per protocol.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2011
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. 10 women between the ages of 18-35 inclusive at time of signing Informed Consent Form.
  2. In good general health off of current medications which may confound response to study medications.
  3. Desire to seek pregnancy actively during the study period by IVF-ICSI.
  4. A normal uterine cavity must have been confirmed by either hydrosonogram or hysteroscopy within two years of entering the study.
  5. Ability to use the required medications.
  6. Day 3 FSH level < 12 IU/ml

Exclusion Criteria:

  1. Current pregnancy
  2. Patients with significant anemia (Hemoglobin < 10 mg/dL).
  3. Patients enrolled simultaneously into other investigative studies that would interfere with this research study.
18 Years to 35 Years
Contact information is only displayed when the study is recruiting subjects
United States
IRB 0120080226
Peter G. McGovern, MD, UMDNJ-NJMS
University Reproductive Associates
Not Provided
Principal Investigator: Peter G. McGovern, MD UMDNJ-NJMS
University Reproductive Associates
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP